

Supplemental figure 1. PSA levels before and in the course of DCVAC/PCa treatment



Supplemental figure 2. Immunological response in the peripheral blood during DCVAC/PCa treatment. (**a**) The proportion of $CD3^+$ was significantly increased after the treatment in 27 evaluated patients, *p<0.05. The proportions of $CD3^+HLA\text{-}DR^+$, $CD4^+$ and $CD8^+$ were stable during the course of treatment (**b, c, d**). Data are expressed as the proportion of $CD3^+$ cells among $CD45^+$ cells. The serum concentrations of IgG (**e**) and IgM (**f**) were stable during the course of treatment and the frequency of regulatory T cells ($CD4^+$ $CD25^+$ $FoxP3^+$) was stable after the treatment (**g**). Data are expressed as the proportion of $CD4^+$ $CD25^+$ $FoxP3^+$ Tregs among $CD4^+$ T cells.



Supplemental figure 3. Immunological response in the peripheral blood in subsequent DCVAC/PCa cycle. The proportion of $CD3^+$ (**a**), $CD3^+HLA\text{-}DR^+$ (**b**), $CD4^+$ (**c**) and $CD8^+$ (**d**) were stable during the course of subsequent DCVAC/PCa cycle. Presence of serum IgG and IgM were stable during the course of treatment (**e, f**). The frequency of Tregs ($CD4^+$ $CD25^+$ $FoxP3^+$) was significantly decreased after the subsequent DCVAC/PCa cycle, *$p<0.05$ (**g**). Data are expressed as the proportion of $CD4^+$ $CD25^+$ $FoxP3^+$ Tregs among $CD4^+$ T cells.



Supplemental figure 4. Tumor antigen-specific T cell responses during DCVAC/PCa treatment in the peripheral blood versus those of healthy controls. The frequency of PSA (**a**), MAGE-A1 (**b**) and MAGE-A3 (**c**) specific T cells before and after the treatment compared to healthy controls.



Supplemental figure 5. Correlation graph for antigen-specific T cells against PSA (**a**) and MAGE-A3 (**b**) and antibody concentrations (OD) detected in the peripheral blood of 27 patients.

Additional eligibility requirements:
1) Karnoffsky performance status >80%
2) Absence of hormonal therapy
3) Normal bone marrow, liver and renal function as defined by a WBC > $4x10^9$/l; platelets > $100x10^9$/l; Hct > 30%.
4) Creatinine up to 1.5 fold of the upper limit of normal
5) Bilirubin, AST and ALT up to double value of upper limit of normal
Exclusion criteria:
1) History of primary immunodeficiency
2) A severe allergic or anaphylactic reaction following vaccination
3) The presence of pulmonary, cardiac, or other systemic diseases limiting patient survival
4) Other inappropriate conditions for enrollment as judged by the clinician

Supplemental table 1. Additional eligibility requirements and exclusion criteria for entry into the study